Cognitive & Nootropic

Dihexa

N-hexanoic-Tyr-Ile-(6) aminohexanoic amide

Angiotensin-IV / HGF-mimetic research amide from the WSU lineage. The “10 million × BDNF” line is an assay comparison, not a human cognition RCT. Not an Alzheimer or Parkinson drug.

Not FDA-approved - research chemical
Reviewed by CalcMyPeptide Editorial Team
Last updated: August 2026Evidence: Low1 peer-reviewed citation
Typical research dose
10-40 mg/day (oral/intranasal)
Frequency
1× daily
Half-life
Unknown (central effects persist >48h)
Common vials
N/A (oral)
CAS
1401708-83-3
Molecular weight
407.51 g/mol

Use-case scores

0–10 against the evidence we have, not a gym ranking. Hidden domains do not apply here.

  • Cognition3/10

    Synaptogenesis claims are preclinical HGF/c-Met work. The “10 million × BDNF” line is a potency comparison, not a human cognition RCT. Community/mechanism after haircut: 3.

Compound card

Sequence
N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide
Class
Angiotensin-IV / HGF-mimetic research amide (WSU lineage)
Formula
C21H33N3O4
Status
Not FDA-approved · research use

How it works

Dihexa (N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide) is a synthetic peptide analog of angiotensin IV that acts on hepatocyte growth factor (HGF) receptors. It is reported to be 10^7 (ten million) times more potent than BDNF (Brain-Derived Neurotrophic Factor) at promoting spinogenesis - the formation of new dendritic spines that enable synaptic connections.

Dihexa crosses the blood-brain barrier and promotes synaptogenesis, which may enhance learning, memory, and cognitive function. It was developed at Washington State University as a potential therapeutic for neurodegenerative diseases including Alzheimer's.

Source: PMID: 23123685

Background & History

Dihexa is an angiotensin-IV / HGF-mimetic research amide from the WSU lineage. Assay potency versus BDNF is not a human cognition RCT. Not an Alzheimer or Parkinson drug.

Research Use Cases

  • ✓HGF/c-Met research-amide identity
  • ✓The “10 million × BDNF” line as an assay comparison, not a clinical multiplier
  • ✓Not a stroke, TBI, or dementia protocol

Dosing

PhaseDoseFrequencyNotes
Standard Protocol10 - 40 mgDaily (oral or intranasal)Extremely potent. Effects persist >48h. Not used by SC injection.

Administration

Route / form
Oral or intranasal
Timing
Morning. No fasting requirement.
Empty stomach?
No - Food timing is not critical.

Timeline

Days to weeks
Anecdotal cognitive clarity improvements, enhanced learning and memory formation.
Week 4+
Synaptogenesis effects are cumulative - most users report compounding cognitive benefit.

Who it is for

Cognitive Enhancement / Nootropic

Low

10 million times more potent than BDNF at spinogenesis in vitro. Very limited human data.

Neurodegenerative Disease Research

Low

Developed for Alzheimer's research. Powerful but data is almost entirely preclinical.

Safety & Considerations

Research peptide with very limited human data. Extremely potent - doses measured in mg/day. Oral or intranasal only. Consult a healthcare provider before use.

Regulatory & Legal Status

FDA Status (US)
Research Only
WADA Status (2026)
Not Listed

Not currently on the WADA 2026 Prohibited List. Policies may change - verify before competition.

Classification

Research Chemical

US Compounding: Not eligible / not available

⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.

Limits of current evidence

  • No Western Phase 3 cognition label.
  • This site will not treat Alzheimer disease from a peptide page.
  • Potency vs BDNF in an assay is not a 10-million-times smarter claim.

Verdict

Dihexa is a research amide from the angiotensin-IV / HGF story. It is not an Alzheimer drug. Oral or SubQ research use is not a Washington State clinical program.

Interactions & Contraindications

Limited human safety file. Start low if used at all. Avoid with active CNS tumors. This site will not treat Alzheimer disease from a peptide page.

Synergies & Common Stacks

+ Semax →

Two nootropic SKUs. Complementary marketing is not a recovery RCT.

Appears in goal guides

Goal guides are maps, not clinic protocols. A mention here is not a treatment plan.

Cognitive Enhancement & Nootropic Drive

Identity map for Semax, Selank, Noopept, and related nootropic SKUs. BDNF language is mechanism, not a US cognition or stroke indication.

View Protocol →

Cognitive Enhancement Protocol

Neuro 3 Plus bioregulator triad (brain, vessels, liver) plus Semax/Selank, with Dihexa reserved for advanced users.

View Protocol →

Frequently Asked Questions

Is Dihexa injectable?▼
No - typically oral or intranasal at 10-40 mg/day. No reconstitution needed. Not used as a subcutaneous injection.
How potent is Dihexa vs BDNF?▼
Reported to be 10 million times more potent at spinogenesis in vitro. This is receptor-specific potency, not a general nootropic efficacy comparison.

References

  1. Bhargava A et al. “"Facilitating effects of a novel angiotensin IV analogue on recovery from traumatic brain injury".” Journal of Cognitive Neuroscience (2011). PMID: 21544069

Looking for a trusted source? See our recommended suppliers

Independently tested · COA-verified · Save 10% with our exclusive code

See suppliers →
← Back to Peptide Library